CP-866087 FUNDAMENTALS EXPLAINED

Contraindicated (one)bortezomib will boost the amount or result of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Solid or reasonable CYP2C19 inhibitors could maximize mavacamten systemic exposure, causing coronary heart failure on account of systolic dysfunction.Procedure brings about peripheral neuropathy (predominant